Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Therapy in Breast Cancer (Umbrella Study)
NCT04215003Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2020
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib, adebrelimab in breast cancer, sponsored by Fudan University. Started Jan 2020; status: recruiting.
02
Drugs
dalpiciclibadebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04215003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215003.